Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.34 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20621275 | 1.00 | IDO1 (0.42) | IDO1NFE2L2GABRA5GABRA1LCK | |
| SCHEMBL22189146 | 0.81 | IDO1 (0.40) | IDO1GABRA5GABRA1LCKSRC | |
| SCHEMBL20621027 | 0.81 | IDO1 (0.40) | IDO1GABRA5GABRA1LCKSRC | |
| SCHEMBL20620953 | 0.81 | IDO1 (0.40) | IDO1GABRA5GABRA1LCKSRC | |
| SCHEMBL19749271 | 0.70 | IDO1 (0.55) | IDO1GABRA5GABRA1LCKSRC | |
| SCHEMBL13469847 | 0.67 | IDO1 (0.51) | IDO1GABRA5GABRA1LCKBRD9 | |
| SCHEMBL22567191 | 0.66 | GABRA5 (0.43) | IDO1GABRA5GABRA1LCKTDO2 | |
| SCHEMBL3356849 | 0.64 | GABRA5 (0.50) | IDO1GABRA5GABRA1LCKTDO2 | |
| SCHEMBL28650020 | 0.63 | IDO1 (0.49) | IDO1GABRA5LCKTDO2 | |
| SCHEMBL28648691 | 0.63 | IDO1 (0.41) | IDO1GABRA5LCKSRCBRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827639-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200216456-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216456-A1 | TDO2 and IDO1 Inhibitors | IDO1, IDO2, TDO2 | IDO1 1/4885NFE2L2 384/4885GABRA5 2963/4885 |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | IDO1 1/4885NFE2L2 562/4885GABRA5 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.